Abstract
Background Beta-blockers, a class of drugs commonly used to manage blood pressure, have been the subject of research regarding their relationship to prostate cancer risk, prognosis, and treatment. Beta blockers reduce risk and improve prognosis of prostate cancer. Perioperative use of a non-selective beta blocker improves outcome after radical prostatectomy. But a related class of drugs, beta 2 adrenergic agonists, has received little attention in prostate cancer.
Methods We studied the relationship of the beta 2 adrenergic agonist salbutamol to prostate cancer risk and survival. We analyzed FDA MedWatch data to determine whether salbutamol could influence the risk of prostate cancer. We used UK Biobank (UKBB) data to assess the effect of salbutamol on prostate cancer (PC) survival.
Results Salbutamol significantly reduces prostate cancer risk, Proportional Reporting Ratio (PRR) and 95% confidence interval (lower bound; upper bound): 0.131 (0.11; 0.155) and improves prognosis. Mean survival was 7.35 years for subjects not taking salbutamol, 10.5 years for subjects taking salbutamol (p = 0.041, log rank test. To adjust for the effect of age we performed proportional hazards regression, survival time dependent variable, age and salbutamol use independent variables. Salbutamol use was significantly related to survival time (p = 0.016) and independent of the significant effect of age (p < 0.001).
Conclusion Salbutamol and other beta-adrenergic agonists could represent a new class of drugs for treatment of prostate cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part through the computational and data resources and staff expertise provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data sources described in the article are publicly available or can be accessed after approved application to UK Biobank.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data sources described in the article are publicly available or can be accessed after approved application to UK Biobank.
Conflicts of interest: none
This work was supported in part through the computational and data resources and staff expertise provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences.
Data Availability
Data sources described in the article are publicly available or can be accessed after approved application to UK Biobank.
